Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PARG | Q86W56 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.38 |
| ▸ | FEN1 | P39748 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950690 | 0.87 | NSD2 (0.43) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3575927 | 0.82 | HTR6 (0.53) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL17075780 | 0.82 | CYP1A2 (0.42) | SMN1; SMN2LMNAALOX5APFEN1ALDH1A1 | |
| SCHEMBL6161252 | 0.81 | ALDH1A1 (0.43) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2803354 | 0.79 | NSD2 (0.58) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6735794 | 0.78 | ALPL (0.51) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL27584595 | 0.77 | NSD2 (0.43) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1797430 | 0.76 | ADRA2A (0.41) | SMN1; SMN2 | |
| SCHEMBL2936510 | 0.75 | ALPL (0.44) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL2937382 | 0.75 | LMNA (0.39) | NSD2MAPTSMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-2951170-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| EP-2951170-A2 | FLAP MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2015-12-09 | — | — | EP | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| EP-2124563-B1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| US-5998424-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0711162-A4 | IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS | DU PONT MERCK PHARMA (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5545651-A | HYPOTENSIVE AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0711162-A1 | IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-15 | — | — | EP | disclosed |
| US-5395844-A | Hypotensive agents; congestive heart failure | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| US-5389635-A | 4- or 5-heterocyclic substituted imadazoles as angiotensin-II antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994028896-A1 | IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5219856-A | Angiotensin-II antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | NSD2 3079/4885MAPT 4864/4885SMN1; SMN2 3245/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | NSD2 2793/4885MAPT 4867/4885SMN1; SMN2 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.